

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JW (Cayman) Therapeutics Co. Ltd

藥明巨諾（開曼）有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2126)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO RESIGNATION OF DIRECTOR

Reference is made to the announcement (the “**Announcement**”) of JW (Cayman) Therapeutics Co. Ltd (the “**Company**”) dated December 30, 2022 in relation to the resignation of an independent non-executive Director and changes in the composition of the nomination and remuneration committees of the Board.

Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

In addition to the information contained in the Announcement, the Board hereby provides supplemental information on the resignation of the independent non-executive Director. As disclosed in the Announcement, Mr. Li has tendered his resignation due to personal reason. The Company has learnt that Mr. Li applied for resignation due to his intention to pursue other personal commitment and interests. Save as disclosed above, all other information of the Announcement remains unchanged.

By order of the Board
JW (Cayman) Therapeutics Co. Ltd
藥明巨諾（開曼）有限公司*
Yiping James Li
Chairman

Shanghai, PRC, January 3, 2023

As at the date of this announcement, the Board comprises Dr. Yiping James Li as Chairman and executive director, Dr. Krishnan Viswanadhan, Ms. Xing Gao, Dr. Ann Li Lee, Mr. Jinyin Wang, Dr. Cheng Liu as non-executive directors, and Mr. Yiu Leung Andy Cheung, Mr. Kin Cheong Kelvin Ho as independent non-executive directors.

* *For identification purposes only*